SCHEMBL6049238

SCHEMBL6049238

CCOC(=O)c1cc(NS(C)(=O)=O)ccc1Oc1ccc(OC(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.52
▸ KIF11 P52732 1/20 0.52
▸ EPHX2 P34913 1/20 0.49
▸ NR1H4 Q96RI1 1/20 0.49
▸ HPGD P15428 2/20 0.49
▸ RECQL P46063 1/20 0.49
▸ SLC6A4 P31645 4/20 0.48
▸ SLC6A2 P23975 2/20 0.48
▸ SLC6A3 Q01959 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ BRD4 O60885 3/20 0.47
▸ MMP2 P08253 1/20 0.46
▸ MMP13 P45452 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ MAPT P10636 1/20 0.42
▸ PPARD Q03181 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ BCR P11274 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6049257 0.80 SLC6A4 (0.65) PPARGHPGDRECQLSLC6A4SLC6A2
SCHEMBL6049224 0.78 KIF11 (0.60) KIF11EPHX2NR1H4SLC6A4SLC6A2
SCHEMBL14031291 0.76 HPGD (0.64) PPARGHPGDRECQLPOLBMMP2
SCHEMBL3107843 0.75 KIF11 (0.82) KIF11EPHX2NR1H4MMP2ALDH1A1
SCHEMBL3996433 0.75 HPGD (0.59) EPHX2NR1H4HPGDRECQLMMP2
SCHEMBL21491333 0.74 HPGD (0.61) PPARGEPHX2NR1H4HPGDRECQL
SCHEMBL7152737 0.72 F10 (0.46) KIF11EPHX2NR1H4SLC6A4SLC6A2
SCHEMBL6049200 0.70 KIF11 (0.45) KIF11EPHX2NR1H4SLC6A4SLC6A2
SCHEMBL3378495 0.70 KIF11 (1.00) KIF11EPHX2NR1H4ALDH1A1MAPK1
Trifluoroacetic Acid SCHEMBL7152732 0.69 F10 (0.47) SLC6A4SLC6A2SLC6A3BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 PPARG 1955/4885KIF11 2354/4885EPHX2 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback